Leukemia and Myeloproliferative Disorders
Myelodysplastic Syndrome (MDS)
1
| Disease Status and/or Stage | Relapsed/Refractory MDS at Intermediate 2 or High Risk Score |
|---|---|
| Protocol Title | A Phase IIa, Open-label, Randomized Dose Confirmation Study of Oral Clofarabine in Previously Treated Adult Patients with Myelodysplastic Syndromes (MDS) |
| PI | Gail J. Roboz, MD |
| Contact | Tania Curcio, RN 212-746-2571 |
| Key Eligibility | Adults 18 years or greater who have received at least one but no more than two prior treatment regimens for MDS. Must have received either 5-azacytidine or decitabine. Patients must not have been refractory to more than one prior treatment regimen. |
| Treatment Overview | Patients will be randomly assigned to one of two clofarabine doses: 35 mg or 55 mg administered orally for 5 days -- may be repeated every 4-8 weeks Frequent clinic visits will be required for monitoring. Treatment may be continued as long as the patient continues to benefit but may not exceed 8 cycles. |
2
| Disease Status and/or Stage | Low or Intermediate-1 Risk MDS |
|---|---|
| Protocol Title | A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Imtermediate-1 Risk Myelodysplastic Syndrome (MDS) |
| PI | Gail Roboz, MD |
| Contact | Tania Curcio, RN 212-746-2571 |
3
| Disease Status and/or Stage | Highly Tranfused MDS |
|---|---|
| Protocol Title | T2* Cardiac MRI Screening of Highly Transfused Patients with Myelodysplastic Syndrome |
| PI | Eric Feldman, MD |
| Contact | Tania Curcio, RN 212-746-2571 |
Last updated: January 5, 2011 |
 |
